Close Menu

NEW YORK — Women's health diagnostic firm Progenity announced after the close of the market on Monday a 38 percent year-over-year increase in third quarter revenues as test volumes ticked up 12 percent.

For the three-month period ended Sept. 30, Progenity reported $25.9 million in revenue, up from $18.8 million in the year-ago quarter but short of the consensus Wall Street estimate of $34.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.